Roche is teaming up with Gilead on the combination trial, aiming to improve on results of remdesivir alone, which has failed to show mortality benefits in COVID-19 patients.
Latin America has become the new epicenter of the pandemic, with deaths surging in Brazil, Peru, Chile, El Salvador, Guatemala and Nicaragua. A new study has warned that Brazil’s total death toll could rise five-fold to 125,000 by August, potentially exceeding the US.
Roche has begun a Phase III of its Actemra/RoActemra (tocilizumab) in combination with Gilead’s remdesivir as a potential treatment for hospitalized patients with severe COVID-19 pneumonia.
The combination trial is being launched in collaboration with Gilead Sciences Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
In this week's episode: Trump’s executive order more rhetoric than action; industry grapples with Trump pricing plan; Hengrui set for this year’s biggest IPO; Sanofi’s exec’s advice to biotechs; and biotech deal return on investment falls.
BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.
Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.
